The Market Impact of COVID-19 on the Pharma Industry
By

An upcoming DCAT webinar, featuring Graham Lewis, Vice President, Global Pharma Strategy, IQVIA, evaluates the market impact on the COVID-19 pandemic on companies’ pipelines, product launches, and performance and how industry fundamentals and growth prospects have been affected. What can the industry expect going forward?

The COVID-19 pandemic has had an impact on the broader economy and all industries, including the pharmaceutical industry, but how has clinical development, product launches, and overall performance been affected and what can the industry expect going forward? To address those very important questions, the Drug, Chemical & Associated Technologies Association (DCAT) is presenting a webinar, “Pipelines, Product Launches, and Performance: The Market Impact of COVID-19 on the Pharma Industry,” on Tuesday, October 27, from 11:00 AM to 12:30 PM ET, featuring Graham Lewis, Vice President, Global Pharma Strategy, IQVIA.

Graham Headshot

Graham Lewis
Vice President
Global Pharma Strategy
IQVIA

Mr. Lewis is a well-recognized industry expert and widely sought after for his strategic insights for conferences and executive briefings throughout the world, including as a featured speaker at past DCAT Week education programs. The webinar will be moderated by Jim Miller, Content Advisor/Consultant, DCAT, and a preeminent expert in bio/pharmaceutical outsourcing and industry consultant with more than 20 years of experience in the bio/pharmaceutical industry.

As the COVID-19 pandemic remains a major global concern, pharmaceutical companies and their suppliers continue to adjust their operations, including with respect to supply planning, clinical trials, product launches, and the sales impact from new models of customer engagement from physicians and patients. In such a challenging and uncertain environment, pharmaceutical companies and their suppliers must keep fully informed on rapidly changing market conditions and the key trends impacting industry performance. Demand for products and how they are sourced and sold is changing constantly, as is the ability to conduct clinical trials, so industry executives must be fully informed in order to respond quickly and appropriately in this unprecedented market environment.

This 90-minute interactive webinar will provide up-to-the-minute market data and analysis on the current state and medium-term outlook of the global pharmaceutical industry. It will delve deeply into these crucial questions: (1) how have industry fundamentals been impacted in terms of growth prospects and product development; (2) what is the impact and projections for new product launches and the industry’s pipeline; and (3) what may be the “new normal” for the pharma industry, and what can the industry expect going forward?

Further information, including how to register, may be found here.

Leave a Reply

Your email address will not be published.

Recent Feature Articles

Generic Drugs: Blockbusters Facing US Patent Expiry
By

By
A slate of blockbuster drugs is scheduled to come off patent in the near term. Which products and companies face generic-drug incursion? Plus the latest numbers and trends in US generic drug approvals.

Novartis Details Pure-Play Innovative Growth Strategy
By

By
Novartis CEO Vas Narasimhais outlined the company’s strategy of being a “pure-play” innovator drug company focused on five core therapeutic areas with eight potential multi-billion drugs in play.  

CDMO M&A: What Are The Important Moves?
By

By
As we near the fourth quarter of 2022, what have been the key mergers and acquisitions thus far in the CDMO/CMO sector and what new CDMOs/CMOs have entered the market? DCAT Value Chain Insights takes a look.

Industry Radar: Impact Factors for Sourcing
By

By
How is current market volatility, led by inflationary pressures, supply-chain disruptions, and geopolitical uncertainty, impacting sourcing and supply decisions? A look at what is on the industry’s radar.